Roger Li, MD

Cancer Focus:
Bladder Cancer

Dr. Roger Li is a genitourinary oncologist whose clinical practice focuses on the surgical treatment of bladder, prostate cancers. He offers a variety of treatment options, including open, laparoscopic, and robotic-assisted procedures, has led several international clinical trials investigating the safety and efficacy of novel therapeutics in bladder cancer.

Prior to joining Moffitt, Dr. Li completed advanced urologic oncology training at the MD Anderson Cancer Center in Houston, Texas. Dr. Li’s research interest includes the genomic characterization of genitourinary malignancies in attempt to tailor therapy specific to the patient, as well as the development of novel immunotherapeutic and targeted strategies in treating bladder cancer.

Dr. Li’s work has previously been highlighted in several national and international urology meetings. He has authored numerous peer reviewed manuscripts and book chapters on urologic oncology.  In addition, he serves as reviewer for many international urologic journals, including British Journal of Urology International, European Urology Oncology, Journal of Clinical Genitourinary Cancer, and BMC Cancer. A native of California, Dr. Li received his medical degree from the University of California, Irvine, and completed his urologic residency training at Loma Linda University Medical Center. In his spare time, he enjoys spending time with his family, traveling, and watching and playing basketball.

Education & Training

Fellowship:

• University of Texas, MD Anderson Cancer Center -

Residency:

• Loma Linda University Medical Center -

Medical School:

• University of California, Irvine School of Medicine - MD

Clinical Trial 22349
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer
Condition: Genitourinary
Intervention: JNJ-42756493 (Erdafitinib)
Status: Open

Clinical Trial 23300
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Condition: Genitourinary
Intervention: Erdafitinib (); Gemzar (gemcitabine); JNJ-42756493 (Erdafitinib); gemcitabine (); mitomycin c ()
Status: OPEN (SUSPENDED)

Clinical Trial 23598
A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Condition: Genitourinary
Intervention: Sacituzumab tirumotecan ()
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R. Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy. BJU Int. 2025 Sep. Pubmedid: 40932312.
• Wen L, Miyagi H, Spiess PE, Yu A, Mendelsohn CL, Tan WS, Psutka SP, Lerner SP, Cheng L, Dyrskjøt L, Meeks JJ, Shariat SF, Gontero P, Pradere B, Steinberg GD, Kamat AM, Li R. Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapies. Nat Rev Urol. 2025 Sep. Pubmedid: 40931081.
• Titus RS, Mundra V, Velasquez EL, Xu J, Riveros C, Ranganathan S, Porika A, Reddy R, Kaushik D, Kukreja J, Li R, Wallis CJD, Satkunasivam R. The association between prior pelvic radiotherapy for cancer and surgical outcomes in patients undergoing radical cystectomy for bladder cancer: An analysis of national surgical quality improvement program targeted cystectomy database. Urol Oncol. 2025 Sep. Pubmedid: 41006132.
• Myers AA, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore N, Steinberg GD, Witjes JA, Schmidt B, Porten S, Hahn NM, Bree KK, Toumazis I, Zhao H, Kamat AM. Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder. Eur Urol. 2025 Oct. Pubmedid: 41046180.
• Li R, Hensley PJ, Babjuk M, Bukavina L, Psutka SP, Lerner SP, O'Donnell MA, Lotan Y, Bree KK, Redorta JP, McConkey DJ, Lee BH, Mariappan P, Mertens LS, Soloway MS, Svatek RS, Tan WS, Williams SB, Gupta S, Buckley R, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Recommendations for Definitions, Risk Stratification, Management Strategies, and Clinical Trial Design from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Oct. Pubmedid: 41076366.
• Jazayeri B, Wang X, Li R. Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. Eur Urol. 2025 Oct. Pubmedid: 41107180.
• Chang SS, Launer B, Narayan V, Patil D, O'Donnell MA, Hensley PJ, Taylor JA, Li R, Fernandez MI, Zhang H, Krishna V, Vrabac D, Abuzeid WM, Nimgaonkar V, Watson D, Royce TJ, Kiedrowski LA, Joshi A, Konety BR, Spiess PE, Williams SB, Packiam VT, Kamat AM, Lotan Y, Daneshmand S. Computational Histology Artificial Intelligence (CHAI) Enhances Risk Stratification of High-grade Ta Non-muscle-invasive Bladder Cancer in a Multicenter Cohort: Comparison to Current European Association of Urology and American Urological Association Stra. Eur Urol. 2025 Oct.88(4):411-413. Pubmedid: 40514253.
• Katims AB, Tin AL, Assel M, Hensley P, Li R, Margulis V, Matin S, Pallauf M, Clark RK, Raman JD, Singla N, Spiess PE, Coleman J. Predictors and Patterns of Nonurothelial Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma (UCAN Collaboration). J Urol. 2025 Oct.214(4):407-414. Pubmedid: 40526449. Pmcid: PMC12355653.
• Lee MS, Hensley PJ, Igel D, Li R, Clark RK, Bingham N, Pallauf M, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Oncologic and survival outcomes in patients undergoing radical nephroureterectomy with preoperative or iatrogenic dialysis dependence. Urol Oncol. 2025 Nov.43(11):662.e9-662.e15. Pubmedid: 40754548.
• von Deimling M, Furrer M, Bianchi A, Pichler R, Maas M, Tully KH, Longoni M, Mertens LS, Taylor J, Del Giudice F, Li R, Gallioli A, Albisinni S, Crocetto F, Velev M, Afferi L, Mari A, Laukhtina E, Klemm J, Singla N, Fisch M, Spiess PE, Lotan Y, Moschini M, Black PC, Antonelli A, Kiss B, Shariat SF, Pradere B. Impact of timing of computed tomography staging and patient factors on the detection of 'true' cN+ bladder cancer. BJU Int. 2025 Nov.136(5):911-919. Pubmedid: 40631580. Pmcid: PMC12522521.
• Song X, Yu X, Moran-Segura CM, Xu H, Li T, Davis JT, Vosoughi A, Grass GD, Li R, Wang X. ROICellTrack: a deep learning framework for integrating cellular imaging modalities in subcellular spatial transcriptomic profiling of tumor tissues. Bioinformatics. 2025 May.41(5). Pubmedid: 40199763. Pmcid: PMC12085996.
• Scilipoti P, Moschini M, Li R, Lerner SP, Black PC, Necchi A, Rouprêt M, Shariat SF, Gupta S, Morgans AK, Psutka SP, Kamat AM. The Financial Burden of Localized and Metastatic Bladder Cancer. Eur Urol. 2025 May.87(5):536-550. Pubmedid: 39730299.
• de Jong JJ, Proudfoot JA, Daneshmand S, Svatek RS, Narayan V, Davicioni E, Joshi S, Dahmen A, Li R, Inman BA, Shah P, Chaplin I, Wright J, Gibb EA, Lotan Y. Molecular Subtyping for Predicting Pathological Upstaging and Survival Outcomes in Clinically Organ-confined Bladder Cancer Patients Undergoing Radical Cystectomy. Eur Urol Open Sci. 2025 Mar.73:24-30. Pubmedid: 39935941. Pmcid: PMC11810690.
• Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta S. Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). J Immunother Cancer. 2025 Mar.13(3). Pubmedid: 40102029. Pmcid: PMC11927433.
• Guske C, Jazayeri SB, Li R. Re: Amanda A. Myers, Wei Shen Tan, Valentina Grajales, et al. Challenging the Paradigm of "BCG-unresponsive" Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.05.027. Eur Urol. 2025 Mar.87(3):e54-e55. Pubmedid: 39406614.
• Carpinito GP, Gerald T, Hensley PJ, Martin AJ, Pallauf M, Pham J, Li R, Potretzke AM, Spiess PE, Singla N, Raman JD, Coleman J, Matin SF, Margulis V. The role of neoadjuvant systemic therapy for high grade upper tract urothelial carcinoma: Results from the upper tract collaborative network (UCAN). Urol Oncol. 2025 Jun.43(6):390.e1-390.e11. Pubmedid: 39721824.
• Leyderman M, Chandrasekar T, Grivas P, Li R, Bhat S, Basnet A, Shapiro O, Jacob J, Daneshvar MA, Kord E, Bratslavsky G, Goldberg H. Metastasis development in non-muscle-invasive bladder cancer. Nat Rev Urol. 2025 Jun.22(6):375-386. Pubmedid: 39567681.
• Robinson HR, Lakritz S, Pavlick DC, Davis SL, Lieu CH, Eule CJ, Graham LS, Spiess PE, Li R, Kamat AM, Grivas P, Jacob JM, Bratslavsky G, Basnet A, Wong KA, Lin DI, Necchi A, Ross JS, Lam ET. Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study. ESMO Open. 2025 Jun.10(6):105312. Pubmedid: 40499462. Pmcid: PMC12182777.
• Jazayeri B, Li R. Personalized neoantigen vaccines in urologic malignancies. Nat Cancer. 2025 Jun.6(6):916-918. Pubmedid: 40346293.
• Ghodoussipour S, Bivalacqua T, Bryan RT, Li R, Mir MC, Palou J, Psutka SP, Sundi D, Tyson MD, Inman BA. A Systematic Review of Novel Intravesical Approaches for the Treatment of Patients with Non-muscle-invasive Bladder Cancer. Eur Urol. 2025 Jul.88(1):33-55. Pubmedid: 40253283.
• Lotan Y, Li R, Chang SS. Artificial Intelligence Biomarkers Predict Poor Efficacy of Bacillus Calmette-Guérin Rechallenge in Previously Bacillus Calmette-Guérin-Treated Nonmuscle-Invasive Bladder Cancer. J Urol. 2025 Jul.214(1):90-91. Pubmedid: 40239974.
• Wen L, Li R. Editorial Comment. J Urol. 2025 Jul.214(1):31. Pubmedid: 40197089.
• Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2025 Jul. Pubmedid: 40716995.
• Pichler R, van Creij NCH, Mertens LS, Del Giudice F, Koll F, Soria F, Subiela JD, Plage H, Tymoszuk P, Mayr R, Klinglmair G, Seeber A, Pichler M, Günther M, Ormanns S, Compérat E, Li R, Moschini M, Pradére B. FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma. Eur Urol Oncol. 2025 Jul. Pubmedid: 40716983.
• Li R, Villa NY, Yu X, Johnson JO, Borjas G, Dhillon J, Moran-Segura CM, Kim Y, Francis N, Dorman D, Powers JJ, Sexton WJ, Spiess PE, Poch MA, Zemp L, Gilbert SM, Zhang J, Pow-Sang JM, Anderson ARA, Li T, Wang X, Grass GD, Burke JM, Dinney CPN, Rodriguez PC, Jain RK, Mulé JJ, Conejo-Garcia JR. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial. Nat Med. 2025 Jan.31(1):176-188. Pubmedid: 39521884.
• Moussa MJ, Tabet GC, Siefker-Radtke AO, Xiao L, Wilson NR, Gao J, Logothetis CJ, Grivas P, Lee B, Shah AY, Msaouel P, Li R, Clemente LC, Zhao J, Tannir NM, Kamat AM, Hansel DE, Guo CC, Campbell MT, Alhalabi O. Histopathologic Progression and Metastatic Relapse Outcomes in Small Cell Neuroendocrine Carcinomas of the Urinary Tract. Cancer Med. 2025 Jan.14(2):e70594. Pubmedid: 39831734. Pmcid: PMC11744726.
• Basile G, Bandini M, Li R, Poch MA, Necchi A, Spiess PE. Gold standard nephroureterectomy, chemoprophylaxis and surveillance in upper tract urothelial carcinoma. Curr Opin Urol. 2025 Jan.35(1):75-82. Pubmedid: 39529478.
• Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb.87(2):110-122. Pubmedid: 39353825.
• Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB. Predicting Response to Intravesical Bacillus Calmette-Guérin in High-Risk Nonmuscle-Invasive Bladder Cancer Using an Artificial Intelligence-Powered Pathology Assay: Development and Validation in an International 12-Center Cohort. J Urol. 2025 Feb.213(2):192-204. Pubmedid: 39383345.
• Steinmetz AR, Jazayeri B, Pierce M, Mokkapati S, McConkey D, Li R, Dinney CP. Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Feb.25(2):149-159. Pubmedid: 39779686.
• Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Dhrubo D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodriguez-Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw TI. ShinyEvents: harmonizing longitudinal data for real world survival estimation. Res Sq. 2025 Aug. Pubmedid: 40799741. Pmcid: PMC12340904.
• Guske C, Jazayeri SB, Harrs C, Rao N, Davaro F, Xu H, Zemp L, Yu A, Gilbert SM, Poch M, Spiess PE, Sexton W, Linscott J, Li R. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025 Aug.8(4):888-892. Pubmedid: 40670271.
• Lehner K, Li R, Hensley PJ, Clark RK, Pallauf M, Katims A, Bingham N, Thapa P, Boorjian SA, Raman JD, Singla N, Coleman J, Margulis V, Spiess PE, Matin SF, Potretzke AM. Smoking is Associated With Poorer Survival Outcomes Following Nephroureterectomy for Upper Tract Urothelial Cancer. Urology. 2025 Aug. Pubmedid: 40848880.
• Lee J, Chen F, Lopez-Beltran A, Necchi A, Cimadamore A, Spiess PE, Li R, Roy-Chowdhuri S, Montironi R, Golijanin D, Luchini C, Cheng L. Urinary Tumor DNA-based Liquid Biopsy in Bladder Cancer Management: A Systematic Review. Eur Urol Focus. 2025 Aug. Pubmedid: 40753029.
• Pichler R, Subiela JD, Mayr R, Moschini M, Li R, Pradére B. Local Therapy of the Primary Tumor: An Option for Metastatic Urothelial Carcinoma in the Era of Novel Combination Therapies?. Eur Urol Open Sci. 2025 Aug.78:69-71. Pubmedid: 40698267. Pmcid: PMC12281547.
• Gupta S, Hensley PJ, Li R, Choudhury A, Daneshmand S, Faltas BM, Flaig TW, Grass GD, Grivas P, Hansel DE, Hassanzadeh C, Kassouf W, Kukreja J, Mendoza-Valdés A, Moschini M, Mouw KW, Navai N, Necchi A, Rosenberg JE, Ross JS, Siefker-Radtke AO, Taylor J, Willliams SB, Zlotta AR, Buckley R, Kamat AM. Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group. Eur Urol. 2025 Apr. Pubmedid: 40268594.
• Wahlstedt ER, Varadhan AK, Wahlstedt JC, Coughlin E, Perisetla N, Mhaskar R, Bilotta A, Nguyen D, Gilbert SM, Li R, Spiess PE, Huelster HL. Effects of Socioeconomic Deprivation on UTUC Staging, Mortality, and Recurrence. Urology. 2025 Apr.198:58-65. Pubmedid: 39674377.
• de Jong JJ, Proudfoot JA, Daneshmand S, Svatek RS, Naryan V, Gibb EA, Davicioni E, Joshi S, Dahmen A, Li R, Inman BA, Shah P, Chaplin I, Wright J, Lotan Y. A luminal non-coding RNA-based genomic classifier confirms favourable outcomes in patients with clinically organ-confined bladder cancer treated with radical cystectomy. BJU Int. 2025 Apr.135(4):648-656. Pubmedid: 39485082. Pmcid: PMC11913596.
• Barata PC, Zarrabi KK, Bex A, Grivas P, Hermann K, Hofman MS, Li R, Lopez-Beltran A, Padani AR, Powles T, Taplin ME, Loriot Y. Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers. Eur Urol. 2025 Apr.87(4):412-423. Pubmedid: 39638730.
• Cigliola A, Prakash G, Li R, Oualla K, Shilpa G, Kamat AM, Chahoud J, Necchi A, Spiess PE. Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions. Curr Oncol Rep. 2024 Sep.26(9):977-990. Pubmedid: 38847974.
• Linscott J, Li R. Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct.212(4):624-625. Pubmedid: 38912644.
• Skelton WP, Masur J, Thomas J, Fallah P, Jain RK, Ravi P, Mantia C, McGregor BA, Nuzzo PV, Adib E, Zarif TE, Preston MA, Clinton TN, Li R, Steele GS, Kassouf W, Freeman D, Pond GR, Jain RK, Sonpavde GP. Impact of Angiotensin Converting Enzyme Inhibitors on Pathologic Complete Response With Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer. Clin Genitourin Cancer. 2024 Oct.22(5):102143. Pubmedid: 39032202.
• Cigliola A, Prakash G, Li R, Oualla K, Gupta S, Kamat AM, Chahoud J, Necchi A, Spiess PE. Correction to: Current Status and Challenges in Rare Genitourinary Cancer Research and Future Directions. Curr Oncol Rep. 2024 Nov.26(11):1520. Pubmedid: 39179885.
• Mandula JK, Sierra-Mondragon RA, Jimenez RV, Chang D, Mohamed E, Chang S, Vazquez-Martinez JA, Cao Y, Anadon CM, Lee SB, Das S, Rocha-Munguba L, Pham VM, Li R, Tarhini AA, Furqan M, Dalton W, Churchman M, Moran-Segura CM, Nguyen J, Perez B, Kojetin DJ, Obermayer A, Yu X, Chen A, Shaw TI, Conejo-Garcia JR, Rodriguez PC. Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages. Immunity. 2024 May.57(5):1124-1140.e9. Pubmedid: 38636522. Pmcid: PMC11096038.
• Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer. Target Oncol. 2024 May.19(3):447-458. Pubmedid: 38570422.
• von Deimling M, Furrer M, Mertens LS, Mari A, van Ginkel N, Bacchiani M, Maas M, Pichler R, Li R, Moschini M, Bianchi A, Vetterlein MW, Lonati C, Crocetto F, Taylor J, Tully KH, Afferi L, Soria F, Del Giudice F, Longoni M, Laukhtina E, Antonelli A, Rink M, Fisch M, Lotan Y, Spiess PE, Black PC, Kiss B, Pradere B, Shariat SF. Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. BJU Int. 2024 Mar.133(3):341-350. Pubmedid: 37904652.
• Huelster HL, Gould B, Schiftan EA, Camperlengo L, Davaro F, Rose KM, Soupir AC, Jia S, Zheng T, Sexton WJ, Pow-Sang J, Spiess PE, Daniel Grass G, Wang L, Wang X, Vosoughi A, Necchi A, Meeks JJ, Faltas BM, Du P, Li R. Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2024 Mar.85(3):283-292. Pubmedid: 37802683.
• Posada JM, Yakirevich E, Kamat AM, Sood A, Jacob JM, Bratslavsky G, Grivas P, Spiess PE, Li R, Necchi A, Mega AE, Golijanin DJ, Pavlick D, Huang RSP, Lin D, Danziger N, Sokol E, Sivakumar S, Ross JS, Cheng L. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Mod Pathol. 2024 Mar.37(3):100424. Pubmedid: 38219954.
• Li R, Nocera L, Rose KM, Raggi D, Naidu S, Mercinelli C, Cigliola A, Tateo V, Patanè D, Grass GD, Gilbert SM, Sexton WJ, Bandini M, Moschini M, Briganti A, Montorsi F, Spiess PE, Necchi A. Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer. Eur Urol Oncol. 2024 Jun.7(3):614-624. Pubmedid: 38184473.
• von Deimling M, Mertens LS, Furrer M, Li R, Tendijck GAH, Taylor J, Crocetto F, Maas M, Mari A, Pichler R, Moschini M, Tully KH, D'Andrea D, Laukhtina E, Del Giudice F, Marcq G, Velev M, Gallioli A, Albisinni S, Mori K, Khanna A, Rink M, Fisch M, Minervini A, Black PC, Lotan Y, Spiess PE, Kiss B, Shariat SF, Pradere B. The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancer. BJU Int. 2024 Jul.134(1):119-127. Pubmedid: 38470089.
• Davaro F, Davaro E, Li R. Editorial Comment. J Urol. 2024 Feb.211(2):253. Pubmedid: 38193408.
• Liveringhouse C, Sim AJ, Zhang J, Jain RK, Naidu SU, Linkowski L, Zemp LW, Yu A, Sexton WJ, Spiess PE, Gilbert SM, Poch MA, Pow-Sang J, Li R, Manley BJ, Vosoughi A, Dhillon J, Xu H, Torres-Roca JF, Johnstone PAS, Yamoah K, Grass GD. A Single Institution Experience in the Management of Localized Neuroendocrine Carcinoma of the Bladder. Clin Genitourin Cancer. 2024 Dec.22(6):102222. Pubmedid: 39353214.
• Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment. Genome Biol. 2024 Dec.25(1):308. Pubmedid: 39639369. Pmcid: PMC11622564.
• Li R, Hensley PJ, Gupta S, Al-Ahmadie H, Babjuk M, Black PC, Brausi M, Bree KK, Fernández MI, Guo CC, Horowitz A, Lamm DL, Lerner SP, Lotan Y, Mariappan P, McConkey D, Mertens LS, Mir C, Ross JS, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess PE, Svatek RS, Tan WS, Taoka R, Buckley R, Kamat AM. Bladder-sparing Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. 2024 Dec.86(6):516-527. Pubmedid: 39183090.
• Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Aug.26(8):945-958. Pubmedid: 38837106.
• Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug.30(8):2216-2223. Pubmedid: 38844794.
• Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug.30(8):2372. Pubmedid: 38890533.
• Li R, Shah PH, Stewart TF, Nam JK, Bivalacqua TJ, Lamm DL, Uchio EM, Geynisman DM, Jacob JM, Meeks JJ, Dickstein R, Pearce SM, Kang SH, Jung SI, Kamat AM, Burke JM, Keegan KA, Steinberg GD. Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug.30(8):2377. Pubmedid: 38956199.
• Linscott JA, Meeks JJ, Dyrskjøt L, Li R. The Elusive Horizon: Biomarkers in Urothelial Carcinoma. Eur Urol. 2024 Apr.85(4):317-319. Pubmedid: 38278663.
• Davaro F, Davaro E, Rose K, Murthy P, Naidu S, Camperlengo L, Grass GD, Vosoughi A, Jain RK, Zemp L, Yu A, Poch MA, Spiess PE, Gilbert SM, Sexton WJ, Li R. Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma. Urol Oncol. 2023 Sep.41(9):389.e7-389.e13. Pubmedid: 36959058.
• Chandra M, Li R, Parwani A, Carson WE, Pohar K, Sundi D. Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics. Urol Oncol. 2023 Sep.41(9):390.e1-390.e17. Pubmedid: 37061453.
• Li R, Sexton WJ, Dhillon J, Berglund A, Naidu S, Borjas G, Rose K, Kim Y, Wang X, Conejo-Garcia JR, Jain RK, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Zhang J. A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder. Clin Cancer Res. 2023 Oct.29(19):3875-3881. Pubmedid: 37505486.
• Necchi A, Faltas BM, Slovin SF, Meeks JJ, Pal SK, Schwartz LH, Huang RSP, Li R, Manley B, Chahoud J, Ross JS, Spiess PE. Immunotherapy in the Treatment of Localized Genitourinary Cancers. JAMA Oncol. 2023 Oct.9(10):1447-1454. Pubmedid: 37561425.
• Tan WS, Grajales V, Bree K, Li R, Nogueras-Gonzalez GM, Navai N, Dinney C, Kamat AM. Bacillus Calmette-Guérin (BCG) unresponsive non-muscle-invasive bladder cancer: are the subgroups equal?. BJU Int. 2023 Oct.132(4):384-386. Pubmedid: 37246493.
• Peak T, Spiess PE, Li R, Grivas P, Necchi A, Pavlick D, Huang RSP, Lin D, Danziger N, Jacob JM, Bratslavsky G, Ross JS. Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry. Oncologist. 2023 Oct.28(10):e910-e920. Pubmedid: 37196060. Pmcid: PMC10546831.
• Tan WS, McElree IM, Davaro F, Steinberg RL, Bree K, Navai N, Dinney CP, O'Donnell MA, Li R, Kamat AM, Packiam VT. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2023 Oct.6(5):531-534. Pubmedid: 37468392.
• Li R, Naidu S, Fan W, Rose K, Huelster H, Grass GD, Vosoughi A, Dhillon J, Kim Y, Gupta S, Jain RK, Zhang J, Zemp L, Yu A, Poch MA, Spiess PE, Pow-Sang J, Gilbert SM, Sexton WJ. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer. Urol Oncol. 2023 Nov.41(11):457.e17-457.e24. Pubmedid: 37880002.
• Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment. bioRxiv. 2023 Nov. Pubmedid: 38014063. Pmcid: PMC10680839.
• Li R. Organ-sparing precision treatment for muscle-invasive bladder cancer. Nat Med. 2023 Nov.29(11):2709-2710. Pubmedid: 37794252.
• Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ, Mine JA, Hänggi K, Sprenger KB, Innamarato P, Harro CM, Powers JJ, Johnson J, Fang B, Eysha M, Nan X, Li R, Perez BA, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. Immunity. 2023 Nov.56(11):2570-2583.e6. Pubmedid: 37909039. Pmcid: PMC10703011.
• Murthy PB, Naidu S, Davaro F, Spiess PE, Zemp L, Poch M, Jain R, Vosoughi A, Grass GD, Yu A, Sexton WJ, Gilbert SM, Li R. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension. Curr Oncol. 2023 Mar.30(3):3223-3231. Pubmedid: 36975458. Pmcid: PMC10046994.
• Abufaraj M, Li R, Meeks J, Shariat SF. Cytoreductive Surgery in Patients with Urothelial Bladder Cancer. Eur Urol Focus. 2023 Mar.9(2):278-279. Pubmedid: 36509654.
• Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):452. Pubmedid: 37217696.
• Davaro F, Jain R, Li R. Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know. Eur Urol Focus. 2023 Jul.9(4):579-581. Pubmedid: 37202260.
• Rose KM, Huelster HL, Meeks JJ, Faltas BM, Sonpavde GP, Lerner SP, Ross JS, Spiess PE, Grass GD, Jain RK, Kamat AM, Vosoughi A, Wang L, Wang X, Li R. Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nat Rev Urol. 2023 Jul.20(7):406-419. Pubmedid: 36977797.
• Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer. BioDrugs. 2023 Jul.37(4):505-520. Pubmedid: 37256534.
• Fink AKC, DeRenzis AC, Awasthi S, Jahan N, Johnstone PAS, Pow-Sang J, Torres-Roca J, Grass D, Fernandez D, Naghavi A, Tan S, Manley B, Li R, Poch M, Yu A, Little N, Bass E, Ercole CE, Katsoulakis E, Burri R, Smith R, Stanley NB, Vadaparampil ST, Yamoah K. Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM study. Cancer Med. 2023 Jan.12(2):1869-1877. Pubmedid: 35796421. Pmcid: PMC9883445.
• Kumar NB, Bahl S, Dhillon J, Poch M, Manley B, Li R, Schell M, Powsang J. Challenges to Recruiting Men on Active Surveillance for Prostate Cancer in Clinical Chemoprevention Trials. Cancers (Basel). 2023 Feb.15(4). Pubmedid: 36831597. Pmcid: PMC9954186.
• Necchi A, Spiess PE, Costa de Padua T, Li R, Grivas P, Huang RSP, Lin DI, Danziger N, Ross JS, Jacob JM, Sager RA, Basnet A, Li G, Graf RP, Pavlick DC, Bratslavsky G. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden. JAMA Netw Open. 2023 Dec.6(12):e2348002. Pubmedid: 38150257. Pmcid: PMC10753400.
• Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec.41(35):5437-5447. Pubmedid: 37793077. Pmcid: PMC10713193.
• Ghelani GH, Zerdan MB, Jacob J, Spiess PE, Li R, Necchi A, Grivas P, Kamat A, Danziger N, Lin D, Huang R, Decker B, Sokol ES, Cheng L, Pavlick D, Ross JS, Bratslavsky G, Basnet A. HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study. Urol Oncol. 2023 Dec.41(12):486.e15-486.e23. Pubmedid: 37821306.
• Rose KM, Narang G, Rosen G, Labatte C, Dumitrascu C, Campagna J, Yu A, Manley BJ, Spiess PE, Li R, Adibi M, Murray KS, Sexton WJ, Humphreys MR. Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study. BJU Int. 2023 Apr.131(4):471-476. Pubmedid: 36285629.
• Hugar LA, Gilbert SM, Li R. Editorial Comment. J Urol. 2022 Sep.208(3):578. Pubmedid: 35942791.
• Aydin AM, Cheriyan SK, Reich R, Hajiran A, Peyton CC, Zemp L, Yu A, Li R, Poch MA, Spiess PE, Jain R, Zhang J, Sexton WJ, Gilbert SM. Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer. Urol Oncol. 2022 Oct.40(10):453.e19-453.e26. Pubmedid: 35811208.
• Tan WS, Steinberg G, Witjes JA, Li R, Shariat SF, Roupret M, Babjuk M, Bivalacqua TJ, Psutka SP, Williams SB, Cookson MS, Palou J, Kamat AM. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022 Oct.5(5):505-516. Pubmedid: 35718695.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Li R, Sexton W, Manley BJ, Gilbert SM. Comparative effectiveness analysis of first-line immunotherapy versus chemotherapy in metastatic urothelial carcinoma of the bladder. Urol Oncol. 2022 Mar.40(3):107.e11-107.e17. Pubmedid: 34426068.
• Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras-Gonzalez GM, Nagaraju S, Navai N, Grossman HB, Dinney CP, Kamat AM. Implications of Guideline-based, Risk-stratified Restaging Transurethral Resection of High-grade Ta Urothelial Carcinoma on Bacillus Calmette-Guérin Therapy Outcomes. Eur Urol Oncol. 2022 Jun.5(3):347-356. Pubmedid: 33935020. Pmcid: PMC8553807.
• Chaurio RA, Anadon CM, Lee Costich T, Payne KK, Biswas S, Harro CM, Moran C, Ortiz AC, Cortina C, Rigolizzo KE, Sprenger KB, Mine JA, Innamarato P, Mandal G, Powers JJ, Martin A, Wang Z, Mehta S, Perez BA, Li R, Robinson J, Kroeger JL, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity. 2022 Jan.55(1):115-128.e9. Pubmedid: 35021053. Pmcid: PMC8852221.
• Patel SY, Trona N, Alford B, Laborde JM, Kim Y, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Poch MA. Preoperative immunonutrition and carbohydrate loading associated with improved bowel function after radical cystectomy. Nutr Clin Pract. 2022 Feb.37(1):176-182. Pubmedid: 33900647.
• Li R, Gilbert SM. Editorial Comment. J Urol. 2022 Feb.207(2):312-313. Pubmedid: 34994655.
• Diaz KA, Spiess PE, Necchi A, Li R, Bandini M, García-Perdomo HA. How to get involved in clinical research: helpful tips. Can J Urol. 2022 Feb.29(1):11024-11026. Pubmedid: 35150226.
• Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, Li R, Manley B, Fernandez D, Naghavi A, Gage K, Lu-Yao G, Katsoulakis E, Burri RJ, Leone A, Ercole CE, Palmer JD, Vapiwala N, Deville C, Rebbeck TR, Dicker AP, Kelly W, Yamoah K. Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease. J Natl Cancer Inst. 2022 Dec.114(12):1656-1664. Pubmedid: 36053178. Pmcid: PMC9745424.
• Ortíz Restrepo A, Ross JS, Spiess PE, Necchi A, Li R, García-Perdomo HA. Emerging targets in upper tract urothelial carcinomas: the TERT gene. Can J Urol. 2022 Dec.29(6):11378-11383. Pubmedid: 36495580.
• Kumar NB, Hogue S, Pow-Sang J, Poch M, Manley BJ, Li R, Dhillon J, Yu A, Byrd DA. Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome. Cancers (Basel). 2022 Aug.14(16). Pubmedid: 36010981. Pmcid: PMC9406482.
• Aydin AM, Reich RR, Cao B, Cheriyan SK, Hajiran A, Zemp L, Yu A, Poch MA, Sexton WJ, Li R, Gilbert SM. Clinical indications for necessary and discretionary hospital readmissions after radical cystectomy. Urol Oncol. 2022 Apr.40(4):164.e1-164.e7. Pubmedid: 34629281. Pmcid: PMC8960322.
• Petros FG, Choi W, Qi Y, Moss T, Li R, Su X, Guo CC, Czerniak B, Dinney C, McConkey DJ, Matin SF. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma. J Urol. 2021 Sep.206(3):548-557. Pubmedid: 33881933.
• Miles BA, McMullen CP, Sweeny L, Zenga J, Li R, Divi V, Jackson R, Patel UA, Richmon JD. Practice patterns of virtual surgical planning: Survey of the reconstructive section of the American Head and Neck Society. Am J Otolaryngol. 2021 Sep.43(1):103225. Pubmedid: 34571439.
• Chin JL, Lavi A, Metcalfe MJ, Siddiqui K, Dewar M, Petros FG, Li R, Nogueras González GM, Wang X, Nair SM, Ward JF, Pisters L. Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer following Radiation Therapy: A Combined Analysis of Two Centers. J Urol. 2021 Sep.206(3):646-654. Pubmedid: 33908799.
• Li R, Zhang J, Gilbert SM, Conejo-Garcia J, Mulé JJ. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021 Sep.18(9):543-555. Pubmedid: 34183833.
• Li R. Editorial Comment. J Urol. 2021 Sep.206(3):567. Pubmedid: 34121428.
• Li R, Jain RK, Sexton WJ. Re: Andrea Necchi, Laura Marandino, Daniele Raggi, et al. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? Eur Urol 2021;79:713-6. Eur Urol. 2021 Oct.80(4):e99. Pubmedid: 34364728.
• Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain R, Chahoud J, Poch M, Manley BJ, Li R, Sexton W, Gilbert SM. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer. J Urol. 2021 Oct.206(4):924-932. Pubmedid: 34032503.
• Green E, Li R. Editorial Comment. J Urol. 2021 Oct.206(4):883-884. Pubmedid: 34378970.
• Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 2021 Nov.128(5):568-574. Pubmedid: 33484074.
• Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time interval from transurethral resection of bladder tumour to bacille Calmette-Guérin induction does not impact therapeutic response. BJU Int. 2021 Nov.128(5):634-641. Pubmedid: 33783950.
• Patel SY, Kubal TE, Li R, Manley BJ, Gilbert SM, Sexton WJ, Spiess PE, Boulware D, Poch MA. Prevalence of Preoperative Iron Deficiency Anemia: A Case Series Among Patients Undergoing Radical Cystectomy. A A Pract. 2021 May.15(5):e01477. Pubmedid: 33999012.
• Rubino S, Kim Y, Zhou J, Dhillon J, Li R, Spiess P, Poch M, Manley BJ, Pow-Sang J, Gilbert S, Sexton W, Zhang J. Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study. World J Urol. 2021 May.39(5):1539-1547. Pubmedid: 32656671.
• Yuan Z, Fernandez D, Dhillon J, Abraham-Miranda J, Awasthi S, Kim Y, Zhang J, Jain R, Serna A, Pow-Sang JM, Poch M, Li R, Manley B, Fink A, Naghavi A, Torres-Roca JF, Grass GD, Kim S, Latifi K, Hunt D, Johnstone PAS, Yamoah K. Proof-of-principle Phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for Grade Group 5 prostate cancer: safety, feasibility, and exploratory analysis. Prostate Cancer P D. 2021 Mar.24(1):140-149. Pubmedid: 32651467. Pmcid: PMC7882397.
• Hugar LA, Gilbert SM, Sexton WJ, Kamat AM, Li R. Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer. Curr Opin Urol. 2021 Mar.31(2):160-169. Pubmedid: 33394766.
• Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Reply by Authors. J Urol. 2021 Jun.205(6):1620-1621. Pubmedid: 33734859.
• Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
• Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design. J Urol. 2021 Jun.205(6):1612-1621. Pubmedid: 33502236.
• Britt J, Jain R, Li R. Robotic radical nephroureterectomy in a patient with situs inversus totalis. Urol Case Rep. 2021 Jul.37:101688. Pubmedid: 34040986. Pmcid: PMC8141754.
• Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. 2021 Jul.80(1):1-3. Pubmedid: 32861573. Pmcid: PMC7448869.
• Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranisinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. 2021 Jul.128(1):65-71. Pubmedid: 33210440.
• Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy. J Urol. 2021 Jan.205(1):100-108. Pubmedid: 32783489. Pmcid: PMC7864376.
• Hajiran A, Azizi M, Aydin AM, Zemp L, Peyton CC, Dhillon J, Nealon S, Reich RR, Cao B, Li R, Manley BJ, Sexton WJ, Gilbert SM. Reply By Authors. J Urol. 2021 Jan.205(1):108. Pubmedid: 33095102.
• Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, Dyrskjøt L, Kamat AM. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. Eur Urol Oncol. 2021 Dec.4(6):893-903. Pubmedid: 33975782.
• Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N. Oncologic Equipoise Between Robotic and Open Radical Cystectomy. J Endourol. 2021 Aug.35(8):1168-1176. Pubmedid: 33619985.
• Li R, Duplisea JJ, Petros FG, González GMN, Tu SM, Karam JA, Huynh TT, Ward JF. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Eur Urol Oncol. 2021 Aug.4(4):651-658. Pubmedid: 31412007.
• Li R, Lerner SP, Kamat AM. The Who, What, When, Where, and Why of Bacillus Calmette-Guérin-unresponsive Bladder Cancer. Eur Urol. 2021 Apr.79(4):437-439. Pubmedid: 33454163.
• Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol. 2020 Sep.78(3):387-399. Pubmedid: 32143924. Pmcid: PMC7771323.
• Aydin AM, Gage K, Dhillon J, Cheriyan SK, Poch MA, Manley BJ, Li R, Sexton WJ, Spiess PE, Gilbert SM, Pow-Sang JM. Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility. Int J Urol. 2020 Oct.27(10):882-889. Pubmedid: 32767444.
• Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. 2020 Oct.38(10):796.e1-796.e6. Pubmedid: 32430255.
• Bakhshwin A, Berry RS, Cox RM, Li R, Reynolds JP, Rubin BP, McKenney JK. Malignant solitary fibrous tumour of the prostate: four cases emphasising significant histological and immunophenotypical overlap with sarcomatoid carcinoma. Pathology. 2020 Oct.52(6):643-648. Pubmedid: 32758370.
• Li R, Kamat AM. Predictors of Response to Intravesical Therapy. Urol Clin North Am. 2020 Feb.47(1):23-33. Pubmedid: 31757297.
• Liem EIML, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Dat. J Urol. 2020 Feb.203(2):283-291. Pubmedid: 31549936.
• Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol. 2020 Dec.3(1):784. Pubmedid: 33335285. Pmcid: PMC7746703.
• Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol. 2020 Apr.38(4):247-254. Pubmedid: 31953001.
• Peyton CC, Reich RR, Tang D, Alford B, Azizi M, Li R, Sexton WJ, Poch M, Gilbert SM. Identifying and Codifying Complications after Radical Cystectomy: Comparison of Administrative Diagnostic and Procedure Codes, and Clinical Chart Review. J Urol. 2019 Nov.202(5):913-919. Pubmedid: 31219762. Pmcid: PMC7864380.
• Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 May.2(3):286-293. Pubmedid: 31200843.
• Shen J, Ruckle D, Li R, Keheila M, Alsyouf M, Schober J, Tryon D, Stokes P, Ruckle HC, Baron P, De Vera M, Baldwin DD. How a Donor Nephrectomy Population Can Help Give Perspective to the Effects of Renal Parenchymal Preservation During Partial Nephrectomy. J Endourol. 2019 May.33(5):417-422. Pubmedid: 30838888.
• Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol. 2019 Mar.37(12):2691-2698. Pubmedid: 30864005.
• Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 Jun.37(6):354.e19-354.e26. Pubmedid: 30777393. Pmcid: PMC6511295.
• Li R, Spiess PE, Gilbert SM, Necchi A. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol. 2019 Jul.76(1):4-6. Pubmedid: 30833139.
• Li R, Zhang M, Duplisea JJ, Troncoso P, Ward JF. Detection and Treatment of Primary Prostatic Melanoma. Urology. 2019 Jan.123:16-19. Pubmedid: 30195014.
• Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol. 2019 Jan.75(1):8-10. Pubmedid: 30301695.
• Duplisea JJ, Mason RJ, Reichard CA, Li R, Shen Y, Boorjian SA, Dinney CP. Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2019 Feb.13(2):24-28. Pubmedid: 30138098. Pmcid: PMC6363565.
• Li R, Spiess PE, Gilbert SM, Necchi A. Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. Eur Urol 2019;76:4-6. Eur Urol. 2019 Aug.76(2):e34. Pubmedid: 31056228.
• Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. Eur Urol. 2018 Oct.74(4):405-408. Pubmedid: 29685644.
• Kamat AM, Li R, O'Donnell MA, Black PC, Roupret M, Catto JW, Comperat E, Ingersoll MA, Witjes WP, McConkey DJ, Witjes JA. Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. Eur Urol. 2018 May.73(5):738-748. Pubmedid: 29055653.
• Li R, Petros FG, Davis JW. Extended Pelvic Lymph Node Dissection in Bladder Cancer. J Endourol. 2018 May.32(S1):S49-S54. Pubmedid: 29774757.
• Petros FG, Keskin SK, Yu KJ, Li R, Metcalfe MJ, Fellman BM, Chang CM, Gu C, Tamboli P, Matin SF, Karam JA, Wood CG. Intraoperative Conversion From Partial to Radical Nephrectomy: Incidence, Predictive Factors, and Outcomes. Urology. 2018 Jun.116:114-119. Pubmedid: 29578041.
• Li R, Metcalfe M, Kukreja J, Navai N. Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review. Bladder Cancer. 2018 Jan.4(1):31-40. Pubmedid: 29430505. Pmcid: PMC5798530.
• Li R, Baack Kukreja JE, Kamat AM. Secondary Tumors After Urinary Diversion. Urol Clin North Am. 2018 Feb.45(1):91-99. Pubmedid: 29169454.
• Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int. 2018 Feb.121(2):244-251. Pubmedid: 28872778. Pmcid: PMC5780258.
• Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF. The use of PET/CT in prostate cancer. Prostate Cancer P D. 2018 Apr.21(1):4-21. Pubmedid: 29230009.
• Li R, Petros FG, Davis CJ, Ward JF. Characterization of Glomus Tumors of the Kidney. Clin Genitourin Cancer. 2017 Sep. Pubmedid: 28967505.
• Shen JK, Faaborg D, Rouse G, Kelly I, Li R, Alsyouf M, Myklak K, Distelberg B, Staack A. Applying translabial ultrasound to detect synthetic slings-You can do it too! A comparison of urology trainees to an attending radiologist. Neurourol Urodyn. 2017 Sep.36(7):1763-1769. Pubmedid: 28185316.
• Li R, Ruckle D, Keheila M, Maldonado J, Lightfoot M, Alsyouf M, Yeo A, Abourbih SR, Olgin G, Arenas JL, Baldwin DD. High-Frequency Dusting Versus Conventional Holmium Laser Lithotripsy for Intrarenal and Ureteral Calculi. J Endourol. 2017 Mar.31(3):272-277. Pubmedid: 27960541.
• Li R, Sylvester R, Dinney CP, Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer. 2017 Jul.3(3):147-148. Pubmedid: 28824941. Pmcid: PMC5545908.
• Li R, Amrhein J, Cohen Z, Champagne M, Kamat AM. Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients. Bladder Cancer. 2017 Jan.3(1):65-71. Pubmedid: 28149937. Pmcid: PMC5271425.
• Khater N, Keheila M, Lightfoot M, Shen J, Abourbih S, Alsyouf M, Li R, Baldwin DD. Predictors of narcotic use after percutaneous nephrolithotomy. Can J Urol. 2017 Feb.24(1):8634-8640. Pubmedid: 28263128.
• Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 Dec.3(6):577-583. Pubmedid: 28753816. Pmcid: PMC5767145.
• Abourbih S, Alsyouf M, Yeo A, Martin J, Vassantachart JM, Lee M, Maldonado J, Lightfoot M, Li R, Olgin G, Baldwin DD. Renal Pelvic Pressure in Percutaneous Nephrolithotomy: The Effect of Multiple Tracts. J Endourol. 2017 10.31(10):1079-1083. Pubmedid: 28791874.
• Li R, Hu B. Recognition and Management of Ectopic Ureterocele During Robotic Assisted Laparoscopic Radical Prostatectomy. Urol Case Rep. 2016 Sep.8:15-17. Pubmedid: 27313987. Pmcid: PMC4906080.
• Arenas JL, Shen JK, Keheila M, Abourbih SR, Lee A, Stokes PK, Li R, Alsyouf M, Lightfoot MA, Baldwin DD. Kidney, Ureter, and Bladder (KUB): A Novel Grading System for Encrusted Ureteral Stents. Urology. 2016 Nov.97:51-55. Pubmedid: 27421780.
• Li R, Petros FG, Kukreja JB, Williams SB, Davis JW. Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy. Investig Clin Urol. 2016 Dec.57(Suppl 2):S155-S164. Pubmedid: 27995219. Pmcid: PMC5161019.
• Li R, Choi W, Ferguson Rd JE, Metcalfe MJ, Kamat AM. New discoveries in the molecular landscape of bladder cancer. F1000Res. 2016 Dec.5:2875. Pubmedid: 28105319. Pmcid: PMC5225406.
• Khater N, Shen J, Arenas J, Keheila M, Alsyouf M, Martin JA, Lightfoot MA, Li R, Olgin G, Smith JC, Baldwin DD. Bench-Top Feasibility Testing of a Novel Percutaneous Renal Access Technique: The Laser Direct Alignment Radiation Reduction Technique (DARRT). J Endourol. 2016 11.30(11):1155-1160. Pubmedid: 27758120.
• Li R, Ruckle HC, Schlaifer AE, El-Shafei A, Yu C, Jones JS. The Effect of Androgen Deprivation Therapy Before Salvage Whole-gland Cryoablation After Primary Radiation Failure in Prostate Cancer Treatment. Urology. 2015 May.85(5):1137-1142. Pubmedid: 25799176.
• Vassantachart JM, Lightfoot M, Yeo A, Maldonado J, Li R, Alsyouf M, Martin J, Lee M, Olgin G, Baldwin DD. Laser fiber cleaving techniques: effects on tip morphology and power output. J Endourol. 2015 Jan.29(1):84-89. Pubmedid: 24964275.
• Li R, Lightfoot M, Alsyouf M, Nicolay L, Baldwin DD, Chamberlin DA. Diagnosis and management of ureteral fibroepithelial polyps in children: a new treatment algorithm. J Pediatr Urol. 2015 Feb.11(1):22.e1-22.e6. Pubmedid: 25218353.
• Alsyouf M, Smith DL, Olgin G, Heldt JP, Lightfoot M, Li R, Baldwin DD. Comparing stone attenuation in low- and conventional-dose noncontrast computed tomography. J Endourol. 2014 Jun.28(6):704-707. Pubmedid: 24517291.
• Li R, Ruckle HC, Creech JD, Culpepper DJ, Lightfoot MA, Alsyouf M, Nicolay L, Jellison F, Baldwin DD. A prospective, randomized, controlled trial assessing diazepam to reduce perception and recall of pain during transrectal ultrasonography-guided biopsy of the prostate. J Endourol. 2014 Jul.28(7):881-886. Pubmedid: 24641687.
• Olgin G, Alsyouf M, Han D, Li R, Lightfoot M, Smith D, Nicolay L, Ruckle H, Baldwin DD. Postoperative cystogram findings predict incontinence following robot-assisted radical prostatectomy. J Endourol. 2014 Dec.28(12):1460-1463. Pubmedid: 25380408.
• Lightfoot M, Li R, Alsyouf M, Nicolay L, Chamberlin D. Transurethral needle biopsy: a novel technique for pathologic diagnosis of bladder tumors in children. J Pediatr Urol. 2014 Dec.10(6):1280-1282. Pubmedid: 25082712.
• Lightfoot M, Ng C, Engebretsen S, Wallner C, Huang G, Li R, Alsyouf M, Olgin G, Smith JC, Baldwin DD. Analgesic use and complications following upper pole access for percutaneous nephrolithotomy. J Endourol. 2014 Aug.28(8):909-914. Pubmedid: 24548123.
• Blair B, Huang G, Arnold D, Li R, Schlaifer A, Anderson K, Engebretsen S, Wallner C, Olgin G, Baldwin DD. Reduced fluoroscopy protocol for percutaneous nephrostolithotomy: feasibility, outcomes and effects on fluoroscopy time. J Urol. 2013 Dec.190(6):2112-2116. Pubmedid: 23764072.
• Li R, Louie MK, Lee HJ, Osann K, Pick DL, Santos R, McDougall EM, Clayman RV. Prospective randomized trial of three different methods of nephrostomy tract closure after percutaneous nephrolithotripsy. BJU Int. 2011 May.107(10):1660-1665. Pubmedid: 20973909.
• Arellano-Garcia ME, Li R, Liu X, Xie Y, Yan X, Loo JA, Hu S. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci. 2010 Sep.11(9):3106-3121. Pubmedid: 20957082. Pmcid: PMC2956083.
• Kolla SB, Gamboa AJ, Li R, Santos RT, Gan JM, Shell C, Andrade L, Louie MK, Clayman RV, McDougall EM. Impact of a laparoscopic renal surgery mini-fellowship program on postgraduate urologist practice patterns at 3-year followup. J Urol. 2010 Nov.184(5):2089-2093. Pubmedid: 20850830.
• Liss MA, Osann K, Canvasser N, Chu W, Chang A, Gan J, Li R, Santos R, Skarecky D, Finley DS, Ahlering TE. Continence definition after radical prostatectomy using urinary quality of life: evaluation of patient reported validated questionnaires. J Urol. 2010 Apr.183(4):1464-1468. Pubmedid: 20171689.

• Title: Clinical Risk Stratification and Tumor Heterogeneity Assessment in Upper Tract Urothelial Carcinoma
  Award Number: 1447186
  Sponsor: American Urological Association (AUA)
  Di N. (PD/PI), Li, R. ()
• Title: A Phase 1 Study of CG0070 in Intermediate Risk Non-Muscle Invasive Bladder Cancer
  Award Number: BCAN CDA
  Sponsor: BLADDER CANCER ADVOCACY NETWOR
  Li, R. (PD/PI)
• Title: Identifying Histopathologic and Molecular Characteristics that Predicts Recurrence in Low Grade Non-Muscle Invasive Bladder Cancer
  Award Number: N/A
  Sponsor: HOPE FOUNDATION
  Li, R. (PD/PI)
• Title: The Role of ctDNA in the Management of Urothelial Cancer
  Award Number: 21VA019-AR1, Second Amendment
  Sponsor: PREDICINE, INC
  Li, R. (PD/PI)
• Title: Identifying Risk Factors for Progression and Recurrence in NMIBC Using Artificial Intelligence
  Award Number: 22VA014-S2
  Sponsor: VALAR LABS INC
  Li, R. (PD/PI)
• Title: Impact of Tertiary Lymphoid Structures (TLSs) in Oncolytic Virus-Induced Tumor Elimination
  Award Number: HT94252510568
  Sponsor: Department of Defense (DOD)
  Li, R. (PD/PI)
• Title: Urinary ctDNA for Bladder Cancer Monitoring
  Award Number: NA
  Sponsor: Moffitt Cancer Center
  Li, R. (PD/PI)
• Title: Decoding the Resistance Mechanisms to Oncolytic Virotherapy in Muscle Invasive Bladder Cancer
  Award Number: W81XWH-22-1-0395
  Sponsor: Department of Defense (DOD)
  Li, R. (PD/PI)